Market Cap 242.07M
Revenue (ttm) 0.00
Net Income (ttm) -105.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,618,100
Avg Vol 3,232,778
Day's Range N/A - N/A
Shares Out 57.91M
Stochastic %K 23%
Beta 0.54
Analysts Hold
Price Target $4.90

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
Fenderstrat68
Fenderstrat68 Aug. 8 at 9:34 PM
$CAPR After hrs of research, which unfortunately I cannot copy paste here, as it would take me 50 posts..and hrs, I can post this final answer from Chatgpt. I used documents available to everyone, and rather than emotionally charged rhetoric, I wanted actual data. I asked for a matrix where to plug wuestions and assign votes 0 to 5 accordingly. I asked AI to assign votes ( so free of bias/emotions) the final resuts were pretty clear.
0 · Reply
TooHot_toTouch
TooHot_toTouch Aug. 8 at 8:40 PM
$CAPR It is possible that FDA wanted to discuss the SAP issues publicly so we received the Adcom. However our No voters were all low in IQ and EQ whereas REPL had a much better panel who actually cared about their patient population.
1 · Reply
NoMonkeyBusiness
NoMonkeyBusiness Aug. 8 at 8:39 PM
$CAPR Ting-Ting better be very careful, Sen. Ron Johnson is gonna get hold of her cell phone too. https://x.com/i/status/2086167213015277658
2 · Reply
dnfrs
dnfrs Aug. 8 at 8:37 PM
$CAPR When Deramiocel is approved for skeletal muscle the approval for cardio will not be far behind. In fact it might be be granted conditionally on a post-marketing phase 4 trial. If there are some positive attitude changes in the FDA following the skeletal muscle approval I can see the phase 4 plan being jointly worked out in a very rapid manner! Meanwhile the Lancet article which speaks of real benefits to both skeletal and cardiac muscle will be circulated widely to doctors and the DMD community. The sooner the approval, the better for the DMD boys and young men!
0 · Reply
BossTrade
BossTrade Aug. 8 at 8:34 PM
$CAPR Chat gpt is a POS program with a serious sycophant bias. That is precisely what you DONT want in an ai program algo
0 · Reply
ezimon
ezimon Aug. 8 at 8:23 PM
$CAPR ok thanks, but why should we give a f.ck about your chatGPT wisdoms? I can tell you that I don't care if it gets approved this month or not, eventually it will get approved. Or are you claiming that it will never get approved anywhere in the world?
0 · Reply
drbrain00
drbrain00 Aug. 8 at 8:13 PM
$CAPR One good news is that Capricor might settle with NS Pharma and let them handle the commercialization. With the possibility of reduced sales without cardiomyopathy and CAPR on the back foot with ADCOM, this case may get settled. I noticed they pulled all the open job listings from their website
2 · Reply
patatechaude
patatechaude Aug. 8 at 8:05 PM
$CAPR 2. FDA… let’s fix the damage done and bring the first ever drug that stops DMD decline to the boys who need it. Don’t let a few bad apples at the FDA that look like they’re still following the Prasad doctrine destroy the only ever drug that works for DMD. FDA, Talk to parents and listen to them. Deramiocel works.
1 · Reply
Spanish_guy
Spanish_guy Aug. 8 at 8:04 PM
$CAPR chat gpt put 30% odds that FDA approval...
2 · Reply
patatechaude
patatechaude Aug. 8 at 8:02 PM
$CAPR 1. Prior to Prasad and Makary the FDA was collaborating with Capricor, understanding that the DMD boys needed help and that Deramiocel was showing signs of effectiveness and safety. They were then trying to find the best approach to bring Deramiocel to the boys. Prior to Prasad and Makary, the FDA was showing signs that together with scientists, relief could be brought to patients of rare diseases. That together progress could be made. Then Prasad takes over and all collaboration is gone. Prasad’s doctrine is to not work with scientists, to keep them in a vacuum. And that’s what happened. Capricor reached out and got no answer. No answer for a very complex rare disease trial. And then the back stabbing by a couple young statisticians, (knowlingly?) using the worst SAP, something that never was agreed on… in an attempt to destroy years of hard work from Capricor. What is behind all of that? Big pharma? The stock market? We’ll find out eventually, because this is not normal.
0 · Reply
Latest News on CAPR
Capricor Therapeutics downgraded to Hold from Buy at Maxim

2026-07-30T12:45:32.000Z - 9 days ago

Capricor Therapeutics downgraded to Hold from Buy at Maxim


FDA panel votes 9-3 against Capricor’s deramiocel

2026-07-29T22:20:22.000Z - 9 days ago

FDA panel votes 9-3 against Capricor’s deramiocel


Caprock Announces Closing of Private Placement

Jun 19, 2026, 5:47 PM EDT - 7 weeks ago

Caprock Announces Closing of Private Placement


Caprock Announces Proposed Private Placement

Jun 12, 2026, 6:02 PM EDT - 2 months ago

Caprock Announces Proposed Private Placement


Capricor Therapeutics Slides: Corporate presentation

May 29, 2026, 7:00 AM EDT - 2 months ago

Capricor Therapeutics Slides: Corporate presentation


Capricor Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Earnings Call Transcript: Q1 2026


Capricor Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Earnings release: Q1 2026


Capricor Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Quarterly report: Q1 2026


Capricor Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Capricor Therapeutics Proxy statement: Proxy filing


Capricor Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 4 months ago

Capricor Therapeutics Proxy statement: Proxy filing


Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025


Capricor Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Capricor Therapeutics Annual report: Q4 2025


Capricor Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 5 months ago

Capricor Therapeutics Earnings release: Q4 2025


Capricor Therapeutics Transcript: Study Result

Dec 17, 2025, 1:00 PM EST - 8 months ago

Capricor Therapeutics Transcript: Study Result


Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

Capricor Therapeutics Transcript: Status Update


Capricor Therapeutics Press release: Status Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

Capricor Therapeutics Press release: Status Update


Capricor Therapeutics Slides: Status Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

Capricor Therapeutics Slides: Status Update


Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025


Capricor Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Capricor Therapeutics Quarterly report: Q3 2025


Capricor Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Capricor Therapeutics Earnings release: Q3 2025


Capricor Therapeutics Slides: Corporate Presentation

Oct 13, 2025, 7:00 AM EDT - 10 months ago

Capricor Therapeutics Slides: Corporate Presentation


Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Capricor Therapeutics Transcript: Study Update


Capricor Therapeutics Press release: Study Update

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Capricor Therapeutics Press release: Study Update


Fenderstrat68
Fenderstrat68 Aug. 8 at 9:34 PM
$CAPR After hrs of research, which unfortunately I cannot copy paste here, as it would take me 50 posts..and hrs, I can post this final answer from Chatgpt. I used documents available to everyone, and rather than emotionally charged rhetoric, I wanted actual data. I asked for a matrix where to plug wuestions and assign votes 0 to 5 accordingly. I asked AI to assign votes ( so free of bias/emotions) the final resuts were pretty clear.
0 · Reply
TooHot_toTouch
TooHot_toTouch Aug. 8 at 8:40 PM
$CAPR It is possible that FDA wanted to discuss the SAP issues publicly so we received the Adcom. However our No voters were all low in IQ and EQ whereas REPL had a much better panel who actually cared about their patient population.
1 · Reply
NoMonkeyBusiness
NoMonkeyBusiness Aug. 8 at 8:39 PM
$CAPR Ting-Ting better be very careful, Sen. Ron Johnson is gonna get hold of her cell phone too. https://x.com/i/status/2086167213015277658
2 · Reply
dnfrs
dnfrs Aug. 8 at 8:37 PM
$CAPR When Deramiocel is approved for skeletal muscle the approval for cardio will not be far behind. In fact it might be be granted conditionally on a post-marketing phase 4 trial. If there are some positive attitude changes in the FDA following the skeletal muscle approval I can see the phase 4 plan being jointly worked out in a very rapid manner! Meanwhile the Lancet article which speaks of real benefits to both skeletal and cardiac muscle will be circulated widely to doctors and the DMD community. The sooner the approval, the better for the DMD boys and young men!
0 · Reply
BossTrade
BossTrade Aug. 8 at 8:34 PM
$CAPR Chat gpt is a POS program with a serious sycophant bias. That is precisely what you DONT want in an ai program algo
0 · Reply
ezimon
ezimon Aug. 8 at 8:23 PM
$CAPR ok thanks, but why should we give a f.ck about your chatGPT wisdoms? I can tell you that I don't care if it gets approved this month or not, eventually it will get approved. Or are you claiming that it will never get approved anywhere in the world?
0 · Reply
drbrain00
drbrain00 Aug. 8 at 8:13 PM
$CAPR One good news is that Capricor might settle with NS Pharma and let them handle the commercialization. With the possibility of reduced sales without cardiomyopathy and CAPR on the back foot with ADCOM, this case may get settled. I noticed they pulled all the open job listings from their website
2 · Reply
patatechaude
patatechaude Aug. 8 at 8:05 PM
$CAPR 2. FDA… let’s fix the damage done and bring the first ever drug that stops DMD decline to the boys who need it. Don’t let a few bad apples at the FDA that look like they’re still following the Prasad doctrine destroy the only ever drug that works for DMD. FDA, Talk to parents and listen to them. Deramiocel works.
1 · Reply
Spanish_guy
Spanish_guy Aug. 8 at 8:04 PM
$CAPR chat gpt put 30% odds that FDA approval...
2 · Reply
patatechaude
patatechaude Aug. 8 at 8:02 PM
$CAPR 1. Prior to Prasad and Makary the FDA was collaborating with Capricor, understanding that the DMD boys needed help and that Deramiocel was showing signs of effectiveness and safety. They were then trying to find the best approach to bring Deramiocel to the boys. Prior to Prasad and Makary, the FDA was showing signs that together with scientists, relief could be brought to patients of rare diseases. That together progress could be made. Then Prasad takes over and all collaboration is gone. Prasad’s doctrine is to not work with scientists, to keep them in a vacuum. And that’s what happened. Capricor reached out and got no answer. No answer for a very complex rare disease trial. And then the back stabbing by a couple young statisticians, (knowlingly?) using the worst SAP, something that never was agreed on… in an attempt to destroy years of hard work from Capricor. What is behind all of that? Big pharma? The stock market? We’ll find out eventually, because this is not normal.
0 · Reply
Bentradez
Bentradez Aug. 8 at 7:49 PM
$CAPR i am sure this has already been posted but this is the most hope I have had about approval as of late
1 · Reply
ezimon
ezimon Aug. 8 at 7:21 PM
$CAPR the good one.
0 · Reply
aricray
aricray Aug. 8 at 7:17 PM
0 · Reply
NoSwagger
NoSwagger Aug. 8 at 7:15 PM
$CAPR IMO, the FDA's Advisory Committee serves no functional purpose when the individuals are unprepared and unfamiliar with the nuanced data and analysis. Just a big waste of time for everyone involved.
4 · Reply
fibonacci1170
fibonacci1170 Aug. 8 at 7:05 PM
$CAPR I was very very disappointed by Evan Snyder, the acting chair, who voted YES on the adcom. The guy hardly said a word during the ~7-hour adcom, only to end up voting YES, and literally conclude the adcom by saying "this deserves approval conditioned on a phase-4 data collection". Too little, too late. If he felt this way about the drug and the kids, and he saw the FDA+adcom raping Capricor all day long, why the hell did he not propose his ideas EARLIER in the adcom. Why did he not say EARLIER "let us not close this door on kids because of methodological issues". Just 3 more YES votes would have made it a 6-6 tie. You often look back at life and think "I should have said this, done that" ... because some moments don't come by again. How many kids will die because Evan Snyder didn't have the courage ... he will probably think about and regret for the rest of his life. He should.
2 · Reply
TooHot_toTouch
TooHot_toTouch Aug. 8 at 7:04 PM
$CAPR @HamBoneXoXo You have my attention for this sniper accuracy prediction. What is your prediction for this month? -CRL ? -Conditional Approval ? -Full Approval ? And a bonus question: Would a management change help with the communications with the FDA?
1 · Reply
MajorDomo
MajorDomo Aug. 8 at 6:55 PM
$CAPR (2/2) Thus, FDA could potentially conclude that the **totality of evidence supports a clinically meaningful effect on DMD functional progression**, even while rejecting the much weaker claim that HOPE-3 conclusively demonstrated treatment of cardiomyopathy; the principal obstacle is therefore the confirmatory pedigree of the statistical analysis, rather than an absence of evidence that deramiocel benefits patients.
0 · Reply
MajorDomo
MajorDomo Aug. 8 at 6:54 PM
$CAPR Deramiocel could plausibly be approved under an indication focused on **slowing upper-limb functional decline in Duchenne muscular dystrophy**, rather than treatment of cardiomyopathy, because HOPE-3 contains a coherent body of randomized evidence of functional benefit despite the controversy over the final statistical analysis: treatment consistently favored deramiocel across PUL analyses; the later raw-scale analysis showed an approximately **1.08-point PUL advantage (p=0.0503)**, demonstrating that the effect is not merely an artifact of converting PUL to percentage change; the primary percent-change analysis showed a **4.55-percentage-point benefit (p=0.029)**; and mid-level PUL and the clinically tangible DVA “Eat 10 Bites” measure independently favored treatment. These findings are supported by earlier HOPE-2 and long-term extension evidence pointing in the same direction, while deramiocel addresses a severe, relentlessly progressive disease with major unmet need.
1 · Reply
Bobsburgerss
Bobsburgerss Aug. 8 at 6:38 PM
$CAPR Why doesn’t NS just ask for their $50 million back and disappear instead of wasting money on litigation…I’m sure their scientists also agree that this drug works.
2 · Reply
HamBoneXoXo
HamBoneXoXo Aug. 8 at 5:59 PM
$CAPR This room is were P finally met Science. Pic from @Cote0924 Btw, Where are you boy? So you lost it all. I feel bad for you. Really I do! Don’t do anything silly now. I guess biotech is not your thing. Try the money market.
2 · Reply
MihalisB86
MihalisB86 Aug. 8 at 5:41 PM
$CAPR DERAMIOCEL a GODSEND for DMD patients!
0 · Reply
MihalisB86
MihalisB86 Aug. 8 at 5:13 PM
$CAPR The public has spoken , a unanimous 100% yes vote. The proof is in the pudding! Huge month for DMD patients and investors! There will be a huge celebration soon!
1 · Reply